Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in ...
The company described the round as fully subscribed and said the cash should keep operations running into the second half of ...
Vietnam Investment Review on MSN
Kazia Therapeutics appoints Sudha Rao as chief scientific officer
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the ...
Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...
Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...
Endogenous Retroviruses (ERVs), relics from ancient viral infections, form a significant part of vertebrate genomes, including humans, where they constitute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results